论文部分内容阅读
目的观察急性缺血性脑卒中(AIS)患者血清基质金属蛋白酶9(MMP-9)含量变化及依达拉奉的治疗效应。方法发病24h内的AIS患者108例,随机分成依达拉奉治疗组(ET组,58例),常规治疗组(CT组,50例),同时选取门诊健康体检者56例作为对照组(C组)。观察治疗前、治疗第7天和治疗14d后血清MMP-9含量变化和神经功能缺损评分。结果 CT组和ET组治疗前血清MMP-9均高于C组(P<0.01);ET组患者治疗第7天时,血液中MMP-9浓度明显下降(P<0.01),并低于CT组,神经功能缺损评分亦低于CT组(P<0.05)。结论依达拉奉注射液具有脑保护作用,能有效改善AIS患者的神经功能缺损。
Objective To investigate the changes of serum matrix metalloproteinase 9 (MMP-9) and the therapeutic effect of edaravone in patients with acute ischemic stroke (AIS). Methods A total of 108 patients with AIS within 24 hours after onset were randomly divided into edaravone treatment group (ET group, 58 cases) and conventional treatment group (CT group, 50 cases). Meanwhile, 56 outpatients with physical examination were selected as control group (C group). The changes of serum MMP-9 level and neurological deficit score before treatment, 7 days after treatment and 14 days after treatment were observed. Results Serum MMP-9 levels in CT and ET groups were significantly higher than those in C group before treatment (P <0.01). On the 7th day after treatment, the levels of MMP-9 in blood in ET group were significantly decreased (P <0.01) , Neurological deficit score was also lower than CT group (P <0.05). Conclusion Edaravone injection has neuroprotective effect and can effectively improve the neurological deficits in patients with AIS.